The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 02, 2003

Filed:

Jun. 01, 2000
Applicant:
Inventors:

Michael J. Amery, Washington Crossing, PA (US);

Paul Sibbons, Harrow, GB;

Stuart Burnett, Liverpool, GB;

Sally-Anne Rickets, Amersham, GB;

Peter A. D. Edwardson, Leeds, GB;

Jonathan Hughes, Buckinghamshire, GB;

Derek A. Hollingsbee, Neston, GB;

Stewart A. Cederholm-Williams, Oxford, GB;

Horace R. Trumbull, Skillman, NJ (US);

Herman Eugene Griffin, Wakefield, RI (US);

Assignee:

Bristol-Myers Squibb Company, New York, NY (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 3/848 ; A61K 3/174 ; A61F 1/300 ;
U.S. Cl.
CPC ...
A61K 3/848 ; A61K 3/174 ; A61F 1/300 ;
Abstract

In accordance with the present invention it has been found that a fibrin polymer film formed by applying materials most closely resembling the natural clotting materials to a surgical adhesion formation. Preferred embodiments involve application of a fibrin monomer under polymerizing conditions to the surgical wound site. Unexpectedly, in addition to this improved prevention of adhesions, the more chemically-natural clots, especially the fibrin-monomer based fibrin polymer, also functions as a fibrin sealant, i.e., has adherence, provides hemostasis and promotes wound healing while also functioning as a barrier. In preferred embodiments the novel methods of this invention conveniently use one or more plasma proteins derived from the patient's own blood as to be autologous. Further, the sealant material is preferably substantially free of any added or exogenous enzymes, e.g., thrombin, etc., which catalyze the cleavage of fibrinopeptides A and/or B from fibrinogen. Preferably a fibrin monomer solution is sprayed over the wounded surgical site.


Find Patent Forward Citations

Loading…